NIH Center for Human Immunology, Inflammation, and Autoimmunity (CHI)

A collage of two people and some cells
Credit
NIAID
Credit: NIAID

The NIH Center for Human Immunology, Inflammation, and Autoimmunity (CHI) is a trans-NIH initiative whose mission is to provide a collaborative resource to enable high-dimensional multiplex immune phenotyping for NIH clinical studies.  This is accomplished through a focused team for scientific input, advanced technologies, and informatics support to better understand human immune function and pathophysiology.

The CHI is a translational operation that will serve as a hub for facilitating the interaction of various immunologically oriented NIH investigators with an interest in translational studies while having access to cutting edge advanced technologies.  The center provides technological resources which are often unavailable to individual laboratories due to costs, complexity, novelty, technological understanding and expertise. Technology platforms include but not limited to, transcriptomics, single cell technologies such as CITE-seq, high parameter cytometry, and serum proteomics.

Highlights

Collaboration

CHI provides collaborative support from study design and data generation through computational analysis and biological interpretation towards the goal of understanding immune phenotypes at a systems level. This will be accomplished in full collaboration with the NIH intramural community, and we welcome proposals for selection on a competitive basis for funding considerations via CHI or institutional budget. Collaborations can address cohorts with clinically significant effects or serve as stakeholders for technology development that would benefit the broader NIH community.

The CHI aims to apply our technologies in the context of collaborative studies with an intramural PI, for which we welcome proposals from any NIH institute on any topic involving human samples.  Proposals for collaborations are solicited and selected competitively from a call for proposals. Read more about collaborating with CHI.

Proposal Submissions

  • The CHI is currently evaluating proposals that were due November 10, 2022 and is not accepting additional proposals at this time. Please check back soon for our next call for proposals. Application due date - November 10, 2022
  • Decision notice - December 15, 2022

Read more about submitting a proposal

Main Areas of Focus

The CHI’s aim is to apply contemporary advances in high-dimensional assays which enable collaborators to develop a comprehensive picture of the “immunome” in human samples.  Our focus is to develop and maintain appropriate technology platforms, with dedicated staff trained in their use to generate and analyze immune phenotypes.  Current platforms include: 

  • Sequencing based technologies - CITE-seq and ASAP-seq to profile both hundreds of proteins and the transcriptome or chromatin accessibility in the same single cells using 10x
  • High-dimensional cytometry - Spectral flow phenotyping with 30-40c panels for PBMC, T cell subsets, and specific tissues; and stimulation assays to simultaneously assess 8 phospho-pathways in 20 cell populations
  • Aptamer-based proteomics platform - The SomaScan Assay is a proteomic platform that provides 7,000 highly reproducible measurements of circulating proteins from a single sample of plasma, serum, urine, and more.

Download the CHI Information Sheet

Contact Information

Rachel Tracy, Executive Assistant

Location

10 Center Drive, Room 7N116
Bethesda, MD 20892

NIAID Research Technologies Branch (RTB)

The CHI has partnered with the NIAID RTB to enhance the scientific platforms that are available to NIH investigators. Through this partnership the NIAID RTB provides guidance to the CHI on many facets of technology development and assists the CHI in tailoring its technologies to meet the needs of the NIH community.   


Learn more about NIAID Research Technologies Branch
Content last reviewed on